Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer

Fig. 5

BTG2 is a clinically relevant modulator of tumor progression. Kaplan-Meier curves were generated to assess correlations between B cell translocation gene 2 (BTG2) expression and patient survival. Top and bottom 25 % of patients were used as cutoffs for grouping. a Low BTG2 expression correlates with decreased overall survival of breast cancer patients (all subtypes). b Low BTG2 expression correlates with decreased metastasis-free survival of breast cancer patients (all subtypes). c Low BTG2 expression correlates with decreased overall survival of triple-negative breast cancer (TNBC) patients. Number of patients and p values are indicated in each panel

Back to article page